Daré Bioscience (DARE) Corporate presentation summary

Commercial launches and platform

• Flora Sync LF5 launched in June 2026, with first sales in July; the non-prescription probiotic vaginal capsules are priced at $49 per box of six.

• DARE to PLAY sildenafil cream revenue is expected in Q4 2026 as a 503B-compounded product; listed price is $99 per tube, with pre-fulfillment prescriptions underway.

• Phase 2b ITT results showed no statistically significant differences on primary or secondary endpoints; a post-hoc subset analysis found significant arousal improvement (p=0.04).

• The live DARE Health Hub offers product education, telehealth access, prescription fulfillment, patient engagement and product cross-selling.

• Provider relationships and a July 2026 strategic collaboration with MyMenopauseRx support patient access and commercial reach.

Development pipeline and catalysts

• Ovaprene’s pivotal study is ongoing; enrollment completion is expected in 2026 and topline data in 2027, with the study targeting at least 2,500 menstrual cycles.

• Ovaprene’s latest interim dataset included 339 subjects and ~1,800 cycles, with an interim pregnancy rate of ~9%; the DSMB recommended continuing without modification in May 2026.

• DARE-HPV Phase 2 began in May 2026; the program has up to $10M in non-dilutive funding, of which $9.0M had been received.

• DARE-HRT1 has 503B compounding and Phase 3-enabling activities underway; DARE-VVA1 Phase 2 preparations are underway.

• Phase 1 study preparation is underway for the progesterone ring programs DARE-PTB1 and DARE-FRT1, targeting pregnancy maintenance or IVF luteal-phase support.

Market opportunity and funding

• Addressed markets include ~20M U.S. women with low or no sexual arousal symptoms, ~51M with menopausal symptoms, ~43M contraceptive users and ~6M acquiring a carcinogenic HPV strain annually.

• More than $75M in non-dilutive funding has been awarded since 2018, with support from the Gates Foundation, ARPA-H and NIH/NICHD.

• Awards include $60M+ for contraception programs, $10M for DARE-HPV’s fully funded Phase 2 trial, and $5M+ across preterm-birth, LARC and HPV programs.

• Earlier-stage opportunities include DARE-PDM1, Casea S, DARE-204/214, DARE-LARC1, DARE-RH1 and DARE-PTB2, spanning preclinical through Phase 1 development.